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Background
Immunohistochemical detection of PD-L1 may be used
in the future as a biomarker to help select an immu-
notherapeutic regimen for patients with advanced mela-
noma. For example, patients whose tumors are PD-L1+
may receive anti-PD-1 monotherapy, and those whose
tumors are PD-L1(-) may receive combination anti-PD-1
and anti-CTLA-4. The evaluation of the utility of PD-L1
as a biomarker has been hampered by the different anti-
bodies and assays used. The purpose of this study was
to quantitatively compare staining properties of three
different PD-L1 monoclonal antibodies that have been
used in recent landmark publications.
Methods
Immunohistochemistry for PD-L1 was performed on serial
sections from fourteen formalin-fixed paraffin-embedded
archival melanoma samples using three different monoclo-
nal antibodies: 5h1, SP142, and E1L3N. Slides were imaged
using the Vectra Automated Quantitative Pathology Ima-
ging System, and using intensity thresholds set by two
pathologists, were scored for the percentage of total cells
(melanocytes and immune cells) demonstrating PD-L1
staining. The observed staining intensity in the samples
below the threshold considered to be “positive” by the
pathologists was used as a measure of background staining
for each antibody.
Results
Membranous PD-L1 expression in melanoma samples
detected with 5h1 and SP142 was highly correlated
(Figure 1A, R2 = 0.88, p < 0.0001). However, there was
no significant correlation between the results obtained
with E1L3N vs 5h1 (Figure 1B, R2 = 0.11, p = 0.25) or
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SP142 (Figure 1C, R2 = 0.07, p = 0.36). The best fit line
predicts that a specimen stained with 5h1, which scored
as having 5% membranous PD-L1 expression, would
show 12% PD-L1+ cells (95% confidence interval of
7.5% to 16.1%) when stained with SP142. 5h1 showed
the lowest background staining, with the lowest intensity
of staining in cells that were considered by the patholo-
gists to represent PD-L1-negative cells. SP142 demon-
strated staining properties very close to 5h1, but with
slightly higher background staining intensity. E1L3N
showed a higher background staining intensity than
either of the other two clones, resulting in a less evident
discrimination between PD-L1+ vs. PD-L1(-) cells.
Conclusions
The commercially available clone SP142 demonstrates
comparable staining properties to 5h1, while the E1L3N,
at least under the conditions used in this study, does
not. Similar comparisons including additional proprie-
tary clones, such as 28-8 and 22C3, will be essential in
understanding how best to use reported PD-L1 status
from various assays to guide therapeutic selection in
patients with advanced melanoma.
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